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Abstract
Purpose: Proliferative Diabetic Retinopathy (PDR) and Eales’ Disease (ED) have different aetiologies although they share
certain common clinical symptoms including pre-retinal neovascularization. Since there is a need to understand if the
shared end-stage angiogenic pathology of PDR and ED is driven by common stimulating factors, we have studied the
cytokines contained in vitreous from both patient groups and analyzed the angiogenic potential of these samples in vitro.
Material and Methods: Vitreous samples from patients with PDR (n = 13) and ED (n = 5) were quantified for various
cytokines using a cytokine biochip array and sandwich ELISA. An additional group of patients (n = 5) with macular hole (MH)
was also studied for comparison. To determine the angiogenic potential of these vitreous samples, they were analyzed for
their ability to induce tubulogenesis in human microvascular endothelial cells. Further, the effect of anti-VEGF
(Ranibizumab) and anti-IL-6 antibodies were studied on vitreous-mediated vascular tube formation.
Results: Elevated levels of IL-6, IL-8, MCP-1 and VEGF were observed in vitreous of both PDR and ED when compared to MH.
PDR and ED vitreous induced greater levels of endothelial cell tube formation compared to controls without vitreous (P,
0.05). When VEGF in vitreous was neutralized by clinically-relevant concentrations of Ranibizumab, tube length was reduced
significantly in 5 of 6 PDR and 3 of 5 ED samples. Moreover, when treated with IL-6 neutralizing antibody, apparent
reduction (71.4%) was observed in PDR vitreous samples.
Conclusions: We have demonstrated that vitreous specimens from PDR and ED patients share common elevations of pro-
inflammatory and pro-angiogenic cytokines. This suggests that common cytokine profiles link these two conditions.
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Introduction
Proliferative Diabetic Retinopathy (PDR) and Eales’ Disease
(ED) are potentially blinding vitreoretinal diseases. ED is an
idiopathic inflammatory venous occlusion that primarily affects
the peripheral retina of healthy young men (20–30 years).
Retinal changes in ED include periphlebitis, peripheral non-
perfusion and neovascularization. In addition, visual loss is
characteristically caused by bilateral recurrent vitreous hemor-
rhage [1], [2]. Although PDR and ED have different etiology,
the symptoms and signs of these diseases run parallel to each
other with some differences [3]. We have previously observed
this commonality in the presence of inflammatory cytokines
[interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoat-
tractant protein-1 (MCP-1)] and vascular endothelial growth
factor (VEGF) in vitreous [4].
Angiogenesis is a highly complex and coordinated process
requiring multiple receptors and ligands in endothelial cells for
which VEGF is a pivotal element in a variety of normal and
pathological circumstances [5], [6]. VEGF is upregulated during
retinal hypoxia and levels of this growth factor are raised in the
vitreous of patients with PDR [7], [8] and VEGF-neutralizing
antibodies are now being used for treatment of pathological ocular
angiogenesis and macular oedema [9], [10], [11], [12].
Though the presence of pro-angiogenic and pro-inflammatory
cytokines in the vitreous of PDR and ED patients has been
demonstrated by several studies the functional potential of their
vitreous has never been shown. Therefore, we have investigated
the angiogenic potential of vitreous from these patients using the
endothelial tube formation assay in vitro, and the effects of anti-
VEGF and anti-IL6 neutralizing antibodies on this potential.
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Materials and Methods
Ethics Statement
Patients were recruited in accordance with the Declaration of
Helsinki and with the approval of the Institutional Review Board
(IRB) of Aravind Eye Hospital. Written informed consent as per
the procedure approved by IRB was obtained from the patients
and maintained.
Study Subjects
Consecutive patients scheduled to undergo vitrectomy for
proliferative ED, advanced PDR or Macular Hole (MH) were
prospectively recruited in one of the three treatment groups. The
clinical diagnosis of ED was made on the basis of peripheral
venous sheathing in multiple quadrants in the fellow eye, or the
operated eye, as observed intra-operatively. The patients with
conditions which could secondarily cause venous sheathing, such
as non-inflammatory retinal vein occlusions, diabetic or hyperten-
sive retinopathy, sickle cell retinopathy, ocular inflammatory
conditions like choroiditis, or pars planitis, or associated systemic
infective/autoimmune/other inflammatory disease (as revealed by
history, examination, or investigations), were excluded from the
study. The indications for vitrectomy included best-corrected
visual acuity less than 20/400 due to vitreous haemorrhage of at
least 2 months duration with/without epiretinal membranes;
rhegmatogenous/combined-mechanism retinal detachment; or a
tractional retinal detachment involving the macula. Eventhough,
haemorrhage is an important indication for vitrectomy; small
samples of undiluted vitreous were obtained before isotonic
infusion and aspiration. The samples which contained blood
contamination were excluded from the study.
All the diabetic patients included in this study had type 2
diabetes mellitus. Like ED patients, they were also surgical
inpatients, who presented with advanced PDR, as defined by the
ETDRS study report number 12 [13]. The indications for
vitrectomy were the same as mentioned above for ED patients.
Patients with idiopathic MH were chosen as control. MH is
caused by vitreomacular traction, without any associated retinal
ischaemia, vascular proliferation or inflammation, and is therefore
least likely to be associated with local release of VEGF or other
inflammatory cytokines. MH patients were evaluated to rule out a
history or signs of ocular trauma or any other associated ocular
pathology. The main preoperative investigation in MH was optical
coherence tomography, to assess the morphology of MH for
surgical feasibility and prognosis. MH patients had no systemic
diabetes mellitus. Patients were recruited in accordance with the
Declaration of Helsinki and with the approval of the Institutional
Review Board of Aravind Eye Hospital. Informed consent was also
obtained from the patients. All the cases had no history of a
previous ocular surgery.
Thirteen PDR patients (11 males, 2 females), aged 54.267.8
years (mean 6 SD) having diabetes for 13.069.7 years were
included in the study. All 5 ED patients were males and 31610
years old. Five MH patients (1 female, 4 males) aged 60.468.2
were included as controls. All the PDR and ED patients had
retinal neovascularization and vitreous haemorrhage. As the
etiology is different [14], the ED patients were males and relatively
younger in age. Therefore, this difference in age and sex is
admissible.
Sample Collection
At the beginning of vitrectomy, undiluted vitreous (200–700 ml)
was aspirated via pars plana with a vitreous cutter, before opening
the infusion port. These undiluted vitreous samples (13 PDR,
5 ED and 5 MH) were immediately frozen in aliquots in
polypropylene tube at 280uC until assay.
Cytokine Assay
Vitreous samples (PDR, n = 8; ED, n= 2) were quantified for a
range of cytokines (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1a, IL-1b,
IFN-c, VEGF, TNF-a, MCP-1, EGF) using the Evidence
Figure 1. Scatter plot showing the distribution levels of 12 cytokines in vitreous from PDR (n=8) patients, quantified using
cytokine bio-chip array. Each sample represents the mean of duplicates. Solid line indicates the median. PDR-Proliferative diabetic retinopathy;
ED- Eales’ disease. IL - Interleukins, VEGF- Vascular endothelial growth factor, IFN-c- Interferon gamma, TNF-a - Tumour necrosis factor alpha, MCP-1 -
Monocyte chemoattractant protein-1, EGF - Epidermal growth factor.
doi:10.1371/journal.pone.0107551.g001
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Investigator Cytokine Biochip Array (Randox, UK). For each
sample, this assay was carried out in duplicate. It is a biochip
with multiple cytokine antibodies coated on a solid substrate.
After incubation with vitreous samples, cytokine specific enzyme-
labelled secondary antibodies were added, and the cytokines
were quantified by chemiluminescence using a charged coupled
device (CCD) camera. The standard curves were constructed for
each cytokine and the sample concentration was determined by
the evidence investigator (Randox, UK). As a follow-up, IL-6,
IL-8, MCP-1, and VEGF were also quantified by sandwich
ELISA (BD Biosciences, R & D systems) according to the
manufacturer’s instructions for 5 PDR, 3 ED and 4 MH
samples. The standard curve was prepared using recombinant
human cytokines.
Tubulogenesis assay
Human dermal microvascular endothelial cells (HMECs) were
purchased (PromoCell Gmbh, Heidelberg, Germany) and grown
in T-25 Nunclon culture flasks (Nalge Nunc International,UK)
with medium (PromoCell) supplemented with growth supplements
(PromoCell) and Primocin (50 mg/ml) (Invitrogen,UK). The in
vitro tubulogenesis assay was performed as previously described
using confluent cells of passage four to six [15]. Briefly for each
assay 26104 HMECs in 5 ml were resuspended in 10 ml of vitreous
and mixed with 15 ml of growth factor reduced matrigel (BD
Biosciences,USA) (PDR, n= 6; ED, n= 5, MH n=5). In place of
vitreous 10 ml of medium was used in controls.
In another series of experiments, HMEC cultures were treated
with ranibizumab (RZB) (0.125 mg/ml or 0.25 mg/ml; PDR,
n= 6; ED, n= 5) (Genentech,Inc., South San Francisco) or anti-
IL-6 (0.1 mg/ml; PDR,n= 7;ED,n= 2) neutralizing antibody (R &
D systems, UK). IL-6 was chosen in preference to other cytokines
and chemokines, since it is known to be elevated in vitreous and
plays a role in the pathogenesis of ocular diseases [4], [16], [17].
Moreover, previous studies have demonstrated that IL-6 levels in
aqueous and vitreous fluids from PDR patients significantly
correlate with disease severity [17], [18], [19]. The above mixture
of matrigel, HMEC, and RZB was prepared collectively for 3
assays (n = 3) and anti-IL-6 mixture for 2 assays for each sample.
Thirty microliter aliquots from the mixture were spotted for each
assay onto Nunclon 48-well culture plates. After matrigel
polymerization at 37uC for 30 minutes, blobs were covered with
endothelial cell supplement medium. Tube formation was
observed after 48 hours, phase images were captured in five
regions per well and tube length was quantified using NIS-
Elements software (Nikon, UK). The mean tube length of all the
five regions of triplicate/duplicate was obtained.
Statistical Analysis
The Man-Whitney U test was used to analyse the differences
between the experimental and control groups. Values are expressed
as mean6 SD. All analysis was done using statistical software Stata
11.0. The results were considered significant at P,0.05.
Results
Cytokine Profile
We have earlier demonstrated that significantly higher concen-
trations of IL-6, IL-8, MCP-1 and VEGF were observed in
Table 1. Levels of cytokines in PDR, ED and MH vitreous used for tubulogenesis assay.
Sample Code IL6 (pg/ml) IL8 (pg/ml) VEGF (pg/ml) IL-1b (pg/ml) MCP1 (pg/ml)
*PDR-27 0 0 849.2 - 978.2
* PDR-29 0 0 0 0 0
* PDR-38 260.2 38.0 2401.4 0 2486.9
* PDR-40 225.1 89.4 682.7 0 2571.0
* PDR-45 0 228.3 5805.7 0 1863.6
{ PDR-49 .530 30.1 130.2 0 1349.0
{ PDR-53 0 2.1 20.6 2.1 21.6
{ PDR-58 60.3 604.2 57.5 1.7 .900
{ PDR-61 56.6 55.4 66.0 1.0 .900
{ PDR-66 24.6 44.3 59.1 0.6 1071.0
* ED-09 0 290.2 105.7 23.8 2063.0
* ED-12 175.0 632.6 0 2.0 -
* ED-16 - 148.1 221.2 3.2 -
{ ED-17 38.5 56.9 144.0 0.3 1017.9
{ ED-19 158.9 961.0 204.9 2.6 .900
* MH-09 0 4.9 0 103.7 118.4
* MH-29 0 0 0 35.1 937.8
* MH-35 0 0 0 0 0
* MH-38 0 0 107.8 0 174.0
MH-44 - - - - -
The cytokine levels were analysed by cytokine bio-chip array for 5 PDR, 2 ED vitreous (indicated by {) and the remaining (PDR = 5, ED = 3, MH = 4) by sandwich ELISA
(indicated by*). The values in the table represent the mean concentration duplicate of each sample. For the two ED ({) samples, cytokines not included in this table are:
IL-2, 8.1 pg/ml; IL-4, 7.14 pg/ml; IFN- c, 12.8 pg/ml and less than 1.6 pg/ml for IL-10, TNF-a, IL-1a. 0- Less than the detectable limit; - cytokine not analysed; . Higher
than the maximum detectable limit. PDR - Proliferative diabetic retinopathy; ED - Eales’ disease; MH - Macular Hole.
doi:10.1371/journal.pone.0107551.t001
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vitreous of PDR (n= 25) and ED (n= 10) than in that of MH
patients (n = 25) [4]. The above study also showed strikingly
similar cytokine profile in both PDR and ED vitreous and this
finding is further confirmed by an extremely rapid cytokine
biochip array (Figure 1, Table 1). Moreover, only trace levels of
IL-10, TNF-a, IL1-a, IL1-b and EGF were observed in both
groups.
Endothelial Tube Formation induced by patient vitreous
The tubulogenesis assay is an in vivo correlate of angiogenesis
involving endothelial alignment, elongation and polygonal net-
work [20]. Cytokine concentrations estimated by ELISA or
Biochip for PDR, ED and MH vitreous, which have been used
for tubulogenesis assay, are presented in Table 1. After 48 hours
of culture the endothelial cells in the absence of vitreous formed a
few short tubes and majority of them remained as individual cells
(Fig. 2A). Mean tubular length was 122 mm in control (Fig. 3). In
some of the vitreous samples, there were more prominent
polygonal tubule network and these had correspondingly high
concentrations of VEGF or IL-6 (Fig. 2B and C). On the other
hand, vitreous with only trace amounts of cytokines produced
minimal tubule formation similar to the control (endothelial cells
without vitreous) (Fig. 2D and 3A). Among the 6 PDR vitreous
samples tested, 5 showed a significant increase in tube formation
(mean fold increase ranging from 0.3 to 0.5, P,0.05, Fig. 3A).
Interestingly a similar vascular response pattern was observed
with ED vitreous containing either high (ED-17 and 19; Fig. 2E
and F) or low levels of (ED-09, Fig. 2G) cytokines (Table 1).
Among, the 5 vitreous samples from ED patients 4 showed
significant increase in tube formation (mean fold increase ranging
from 0.1 to 0.7) (P,0.05; Fig. 3B).
In MH patients though the retinal vascular reaction does not
occur in vivo, we observed significant tube formation with vitreous
from all these patients (Fig. 3C). The nature of the vascular
assembly is shown in figure 2H for vitreous of MH-09 which
contained substantial amount of MCP-1 and IL1-b and trace level
of VEGF (Table-1). With limited number of samples studied, it
was not possible to apply a test for correlation. However, the data
indicate that tube formation in vitro is influenced by the levels of
various pro-angiogenic factors present in the vitreous samples.
Effect of RZB on vitreous-induced Endothelial Tube
Formation
HMECs were exposed to clinically-relevant concentrations of
RZB in combination with the each of the vitreous samples from
PDR and ED patients. Tube formation was observed and images
were captured after 48 hours of incubation. Figures 2C and 2I
show the nature of the vascular assembly in the presence or
absence of RZB with PDR-45 vitreous. The tube length was
reduced in all six cases with 0.125 mg/ml RZB and the mean fold
decrease ranged from 0.2 to 0.7 though significantly in 5 cases
(Fig. 4A). Interestingly, we have also observed the reduction in
tube length when ED vitreous was treated with RZB (Fig. 2E and
2J). This anti-VEGF effect was observed in all five cases with a
mean fold decrease ranging from 0.2 to 1.2, though showing a
significant decrease in three cases (Fig. 4B).
Effect of IL-6 neutralizing antibody on vitreous-induced
endothelial tube formation
Since IL-6 was observed at high levels in PDR as well as in ED
vitreous, we carried out another set of experiments to test the effect
of anti-IL6 neutralizing antibody (0.1 mg/ml) on tube formation.
Among seven samples of PDR vitreous tested, tube length was
reduced in 5 samples with a mean fold ranging from 0.06 to 0.3
(Fig. 5A, C and E). Even though a noticeable reduction was
observed in tube length, there was no significant difference
between the groups with anti-IL-6 treatment. Our study included
only two ED samples for anti-IL-6 treatment due to its reduced
availability of clinical samples and limited volume of vitreous; of
the two an apparent reduction in tube length was observed in one
sample (ED -17) (Fig. 5B, D and F).
Figure 2. Representative phase images of tube formation
induced by vitreous from PDR/ED/MH patients in human
dermal microvascular endothelial cell (HMEC). 26105 HMECs in
triplicate were exposed to vitreous alone or with RZB (0.125 mg/ml).
Tube formation was observed and images were captured after 48 hours
incubation. Each panel shows a part of the representative well. The tube
length was quantified by NIS-Elements software (Nikon). Scale bar
= 100 mm. A. Control (without vitreous); B and C - PDR vitreous-induced
tube formation, which had high levels of VEGF/IL-6/MCP-1; D-PDR
vitreous with trace levels of cytokines showing a very few tube
formation. E- G - ED vitreous-induced tube formation as in PDR. H - MH
vitreous. I and J are images of vascular tubes in the presence of PDR/ED
vitreous and anti-VEGF antibody, showing reduction in tube length
compared to C and E respectively. Number in the images denotes the
patient ID as in table 1. PDR - Proliferative diabetic retinopathy; ED-
Eales’ disease; MH- Macular Hole. RZB – Ranibizumab.
doi:10.1371/journal.pone.0107551.g002
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Discussion
Angiogenic growth factors contribute to neovascularization that
occurs in retinal diseases like DR and ED. In these vitreo-retinal
diseases inflammatory processes are also considered to be critical,
suggesting that a range of secreted factors in the vitreous cavity are
associated with pathological processes [21], [22], [23]. The
presence of inflammatory and angiogenic growth factors has been
demonstrated in vitreous [4], [16], [24] from these patients.
Though PDR & ED differ in their etiology the profile of
proangiogenic factors in the vitreous is markedly similar. We
have previously found no significant difference in the concentra-
tion of VEGF, IL-6, IL-8 and MCP-1 between these two diseases
[4]. Moreover, the profile of twelve cytokines is also similar as
shown by cytokine array (Fig. 1, Table 1) and this correlates with
the other assays. This bio-chip approach is rapid and accurate
taking ,4 hours for analysis. It is known that some patients fail to
respond to RZB therapy and in the future there may be a place for
rapid vitreous analysis post-vitrectomy and establishing if certain
growth factors or cytokines are absent or elevated. This would
enable patient-specific tailoring the subsequent therapy.
Figure 3. Angiogenic potential of vitreous in capillary tube formation. Experimental details are as in Fig. 2. (A) PDR vitreous, (B) ED vitreous,
(C) MH vitreous. Bar graph shows the mean concentration of the triplicate of each sample. PDR-proliferative diabetic retinopathy; ED- Eales’ disease;
MH- Macular Hole. Number in X-axis denotes the patient number as in table 1. **P,0.001; *P,0.05.
doi:10.1371/journal.pone.0107551.g003
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Though there have been several reports on the presence of
cytokines in vitreous of patients with vitreo-retinal diseases, to our
knowledge, this is the first study to evaluate the angiogenic
potential of vitreous from these patients. Using the in vitro
tubulogenesis assay, we demonstrated the ability of PDR, ED, MH
vitreous in inducing endothelial tube formation. In general,
markedly increased number of vascular tubes and tubular network
was observed with vitreous from the above patient groups than the
control without vitreous. It is possible that the factors particularly
VEGF, IL-6, IL-8 and MCP-1 might be responsible for vascular
tube formation (Table 1, Fig. 3). Further, in addition to VEGF
which is known to play a significant role in neovascularization in
PDR [25], vitreous containing high levels of IL-6 and IL-8 or
MCP-1 but with trace amount of VEGF also induced network of
vascular tubes. (Table 1; Fig. 3; PDR-40, 49; ED-12, MH-09, 29).
Therefore, in addition to VEGF, inflammatory cytokines are
involved in inducing neovascularization.
There is substantial supporting evidence to indicate the
interrelationship between the expression of inflammatory cytokines
and vascular growth factors in different types of clinical conditions
involving angiogenesis. The expression of IL-6, a multi-functional
cytokine is elevated in tissues that undergo active angiogenesis, but it
does not induce proliferation of endothelial cells. IL-6 has the ability
to induce angiogenesis indirectly by the expression of VEGF [26]
and possibly by increasing endothelial permeability [27].
Certain transcription factors like NF-Kappa B are known to
activate synergistically transcription of cytokines such as IL-6 and
chemokines IL-8 and MCP-1 [28], [29], [30]. Further, transcrip-
tional activation of VEGF by IL-6 via STAT-3 pathway and
transactivation of VEGF-R2 by IL-8 are associated with vascular
permeability [31], [32]. Thus, IL-6, present in significant amount
in vitreous of PDR and ED patients, may be able to function as
indirect inducer of tube formation in vitro. Whether a similar IL-6
induced VEGF expression occurs in the endothelial cells in the
tubulogenesis assay needs further studies.
RZB is a high affinity recombinant Fab which binds to the
receptor–binding site of all biologically active forms of VEGF-A,
thus preventing the activation of two related receptor tyrosine
kinase, VEGFR-1 and VEGFR-2. Consequently, the endothelial
cell proliferation, migration, permeability and vascular assembly
are inhibited by RZB [33], [34], [35]. In this context our study was
designed to evaluate the ability of RZB and anti-IL-6 antibodies to
inhibit the angiogenic ability of PDR and ED vitreous. A marked
reduction in vascular tube formation was observed when PDR
vitreous was treated with RZB although this was not observed in
all the samples. For example among the two PDR vitreous
samples, though both contained low levels of VEGF, tube
formation was significantly reduced by RZB in PDR-53 but not
in PDR-49 and this difference may possibly be due to the presence
of low levels of IL-6 and MCP-1 in the former but high levels of
these cytokines in the latter. In general our results can be
correlated with clinical studies wherein up to 38.6% of PDR
patients did not respond to VEGF therapy [36].
In our context with IL-6 neutralizing antibody we observed tube
length reduction in PDR; however, the reduction was not
significant (Table-1, Fig. 5E). These samples contained high levels
of MCP-1 and varying concentrations of other cytokines. In
general, the present study suggests the involvement of inflamma-
tory cytokines in addition to VEGF in inducing tube formation.
Further studies are required to evaluate the inter-relationship
between the expression of inflammatory cytokines and VEGF as
well as their synergistic activity at the molecular level.
In conclusion, this is the first study to evaluate the angiogenic
potential of vitreous from PDR and ED patients, demonstrating that
VEGF present in ED vitreous is involved in inducing the vascular
endothelial cell migration and assembly. Further, the importance of
proinflammatory factors in addition to VEGF in retinal neovascu-
larization is well-indicated. It is important to note that in patients,
vitreous levels of growth factors and cytokines may not necessarily
be due to the pathophysiology of the respective disease entity, but
from intravitreal blood and associated cell sources such as
thrombocytes. Nevertheless, in this study patient numbers are
limited since the majority of vitreous samples we obtained needed to
be excluded from the study due to blood contamination.
Nevertheless, the study forms a basis for extending patient numbers
and further investigating the cytokine profile in PDR and ED and
how this influences key function endpoints such as pathological
angiogenesis. Therefore, the current data is a useful platform for
extending the investigation by using several functional endothelial
cell migration, proliferation, and permeability assays [37], [38] to
elucidate the importance of various factors (IL-8,MCP-1) and their
Figure 4. Effect of anti-VEGF antibody on vitreous-induced
tube formation. HMECs were mixed with PDR vitreous in presence of
RZB (in triplicate cultures). Tube formation was observed and images
were captured after 48 hours incubation. (A) 0.125 mg/ml of RZB with
PDR vitreous (B) 0.25 mg/ml of RZB with ED vitreous. The tube length
was quantified by Nikon NIS-Elements software. Number in the legend
denotes the patient ID as in table 1. PDR - Proliferative diabetic
retinopathy; ED- Eales’ disease; RZB-Ranibizumab. **P,0.001;*P,0.05.
doi:10.1371/journal.pone.0107551.g004
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interaction in neovascularization, by using the patients’ vitreous and
a combination of neutralizing antibodies.
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